Grüncef (Cefadroxil Monohydrate)

Grüncef is a prescription oral antibiotic that contains the active ingredient cefadroxil monohydrate. It belongs to the first‑generation cephalosporin class and is marketed in the European Union. The product’s specific strength and dosage form are not disclosed in the available data, but it is supplied as a tablet or capsule for systemic use.

Grüncef is indicated for the treatment of several bacterial infections that are susceptible to cefadroxil. It is commonly prescribed by healthcare professionals for the following conditions:

- Uncomplicated skin and soft tissue infections such as cellulitis and impetigo - Acute uncomplicated urinary tract infections caused by susceptible organisms - Respiratory tract infections including pharyngitis, tonsillitis, and bronchitis - Surgical prophylaxis in certain low‑risk procedures - Infections where a first‑generation cephalosporin is appropriate based on culture results

Side effects of Grüncef vary in frequency and severity. Patients should be aware of both common and serious reactions.

Common: - Nausea or vomiting - Diarrhea, which may be mild to moderate - Abdominal discomfort or flatulence - Headache - Rash or mild skin redness - Transient elevation of liver enzymes

Serious: - Severe allergic reactions such as anaphylaxis or Stevens‑Johnson syndrome - Clostridioides difficile‑associated colitis - Significant liver injury (hepatitis, jaundice) - Hematologic abnormalities like neutropenia or thrombocytopenia - Acute interstitial nephritis - Serum sickness‑like reactions

Before starting Grüncef, certain precautions should be considered to minimize risks:

- Assess for a history of hypersensitivity to cephalosporins, penicillins, or other beta‑lactam antibiotics - Use with caution in patients with renal impairment; dosage adjustment may be required - Monitor liver function tests in patients with pre‑existing hepatic disease - Evaluate for gastrointestinal conditions that predispose to C. difficile infection - Consider pregnancy and lactation status; category B indicates no proven risk but discuss with a clinician - Review patient age, as elderly individuals may have increased susceptibility to adverse effects - Ensure appropriate microbiological diagnosis to confirm susceptibility

Grüncef may interact with other medicines, affecting its efficacy or safety. Interactions are grouped by the level of concern.

Avoid: - Concurrent use with other nephrotoxic agents (e.g., aminoglycosides, vancomycin) that may increase kidney injury risk - Combination with anticoagulants such as warfarin, which can enhance bleeding tendencies - Use with probenecid, which can reduce renal clearance of cefadroxil and raise plasma levels

Use with caution: - Oral contraceptives, as antibiotics may reduce contraceptive effectiveness - Diuretics, particularly loop diuretics, which may affect electrolyte balance - Allopurinol, due to potential rash enhancement - Antacids containing aluminum or magnesium, which could interfere with absorption - Immunosuppressants like cyclosporine, requiring monitoring of drug levels